Abstract : To establish a safety profile in patients with Stage IV, EGFr positive breast cancer, for which no curative standard exists, of C225 over a range of dose levels and to pharmacologically optimize the dosing regimen of loading and maintenance infusions administered during combination chemotherapy with weekly doses of paclitaxel.